• About
    • Our Team
    • Our Partners
    • Our Work
  • Tools
    • Case Definitions
    • Vaccine Safety Templates
    • Translations
    • Benefit-Risk Assessment Module
  • Resources
    • News
    • Newsletter
    • Safety by Numbers
    • Webinars
  • Training
    • DSMB Training
    • CDC Training​
    • Vaccine Courses
  • SPEAC
Menu
  • About
    • Our Team
    • Our Partners
    • Our Work
  • Tools
    • Case Definitions
    • Vaccine Safety Templates
    • Translations
    • Benefit-Risk Assessment Module
  • Resources
    • News
    • Newsletter
    • Safety by Numbers
    • Webinars
  • Training
    • DSMB Training
    • CDC Training​
    • Vaccine Courses
  • SPEAC
MPOX
JOIN
Posted on February 19, 2024February 21, 2024

99 Million People Included in Largest Global Vaccine Safety Study

Global Vaccine Data Network utilises vast data sets to detect potential vaccine safety signals 19 February 2024—The Global Vacc...
Read More
Posted on February 5, 2024

Request for Review: Standardized template with key considerations for a benefit/risk assessment for the Comirnaty COVID-19 mRNA vaccine

The proposed mRNA BioNTech/Comirnaty manuscript is ready for peer review. The Brighton Collaboration BRAVATO (Benefit-Risk Asses...
Read More
Posted on January 17, 2024January 31, 2024

New University of Alberta-based study to examine very rare adverse events linked to COVID-19 vaccines

The multimillion-dollar global initiative will study causes and risk factors, to ensure safer vaccines are ready for the next pote...
Read More
Posted on November 9, 2023January 3, 2024

SPEAC’s Real-World Evidence Framework

This editorial by Dr. Robert T. Chen first appeared in the October 2023 issue of Safety by Numbers. It is reposted here with per...
Read More
Posted on October 31, 2023November 20, 2023

Request for Review: TTS-VITT Draft Brighton Case Definition

Dear Brighton Collaboration members: Please find below a draft Brighton Collaboration case definition for both TTS (thrombosis...
Read More
Posted on October 11, 2023October 11, 2023

Understanding the Etiologies of Adverse Events Following Immunization via the International Network of Specialist Immunization Services

This editorial was previously published in Vaccine Safety Quarterly. Karina Top, MD, MS Vaccine safety has been my prim...
Read More
Posted on September 28, 2023January 2, 2024

Request for Review: Autoimmune Hepatitis Case Definition

On behalf of the Brighton Collaboration Autoimmune Hepatitis Case Definition Working Group, please find below a manuscript on “A...
Read More
Posted on May 2, 2023September 21, 2023

BC Peer Review Needed: B-R Assessment Manuscript and Case Study

Digital,digital
Read More
Posted on March 12, 2023September 20, 2023

Maternal Immunization Working Group Meeting Report (November 2022)

On 8 and 9 November 2022, the Maternal Immunization Working Group (MIWG) held an in-person and online hybrid meeting. The objectiv...
Read More
Posted on February 17, 2023August 9, 2023

Reactivation of the Brighton Collaboration Digital Innovations in Vaccine Safety (DIVaS) Working Group

Digital,digital
Read More
Previous page 1 2 3 4 5 Next page

Recent Posts

  • Standardized template with key considerations for a benefit/risk assessment for the emergent vesicular stomatitis virus (VSV) viral vector vaccine for Lassa feverJune 2, 2025
  • Strengthening Vaccine Safety from Outbreaks to Infants: SPEAC at the World Vaccine CongressMay 27, 2025
  • Brighton Collaboration News — May 2025May 19, 2025
  • Safety by Numbers – February 2025February 19, 2025
  • Brighton Collaboration News — Sept 2024September 9, 2024

Email:
bc-coordinator@taskforce.org

Address:
The Task Force for Global Health,
330 W. Ponce de Leon Ave.
Decatur, GA 30030

  • Case Definitions
  • Safety Templates
  • Covid-19
  • Trusted Sources
Linkedin

© Brighton Collaboration  2023. All rights reserved.

  • Disclaimer and Privacy Policy